Based on our Pharmacor advisory service entitled
Breast Cancer, Decision Resources is offering an exclusive analyst call entitled
A Crushing Blow for Avastin? Assessing the Impact of an FDA Panel’s 12 to 1 Vote to Withdraw Avastin’s Marketing Approval for Breast Cancer. Because this presentation will feature major updates, it is
ONLY available to purchasers of this Pharmacor advisory service.
Date & Time
Thursday, July 29, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time
This 15-minute analyst call, presented by Decision Resources Analyst Niamh Murphy, Ph.D., will answer the following questions:
- What will be the effect on physician prescribing if the FDA withdraws Avastin’s indication in HER2-negative breast cancer?
- How will Avastin’s withdrawal from metastatic breast cancer impact the uptake of emerging therapies such as Sanofi-Aventis’ iniparib (BSI-201) and AstraZeneca’s olaparib?
- If the FDA fails to grant Avastin full approval for metastatic breast cancer, how will this impact the overall breast cancer drug market through 2019?
Contact us to learn how you can purchase this service and attend the analyst call.
Click here to view the invite.